The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor cell (CTC) PD-L1 and interferon regulatory factor-1 (IRF-1) expression as biomarkers of anti-PD-(L)1 response.
 
Laura Kennedy
No Relationships to Disclose
 
Arturo B. Ramirez
Employment - RareCyte
Stock and Other Ownership Interests - RareCyte
Patents, Royalties, Other Intellectual Property - RareCyte
Travel, Accommodations, Expenses - Leica Biosystems
 
Lance U'Ren
Employment - RareCyte
Patents, Royalties, Other Intellectual Property - RareCyte
 
Yao Sun
Employment - RareCyte
 
Grace Durenberger
No Relationships to Disclose
 
Laura Quan Man Chow
Consulting or Advisory Role - Alkermes; Amgen; AstraZeneca; Dynavax Technologies; Genentech; Merck; Synthorx; Takeda
Research Funding - ALX Oncology (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); Genentech (Inst); Incyte (Inst); Lilly/ImClone (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Biocept; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Foundation Medicine; Genentech; HERON; Janssen; Merck; Pfizer; QED Therapeutics; Seagen
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncogenex (Inst); Pfizer (Inst)
 
Vijayakrishna K. Gadi
Leadership - SEngine Precision Medicine
Stock and Other Ownership Interests - Sengine precision medicine
Consulting or Advisory Role - Puma Biotechnology; Seagen
Research Funding - Genentech/Roche (Inst)